Flubendazole Enhances the Inhibitory Effect of Paclitaxel via HIF1α/PI3K/AKT Signaling Pathways in Breast Cancer
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms242015121 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Yuxin Zhou und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China. Hauptthemen laut MEDLINE: Paclitaxel, Breast Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities, Post-Doctor Research Project.
Abstract (Originalsprache)
Paclitaxel, a natural anticancer drug, is widely recognized and extensively utilized in the treatment of breast cancer (BC). However, it may lead to certain side effects or drug resistance. Fortunately, combination therapy with another anti-tumor agent has been explored as an option to improve the efficacy of paclitaxel in the treatment of BC. Herein, we first evaluated the synergistic effects of paclitaxel and flubendazole through combination index (CI) calculations. Secondly, flubendazole was demonstrated to synergize paclitaxel-mediated BC cell killing in vitro and in vivo. Moreover, we discovered that flubendazole could reverse the drug resistance of paclitaxel-resistant BC cells. Mechanistically, flubendazole was demonstrated to enhance the inhibitory effect of paclitaxel via HIF1α/PI3K/AKT signaling pathways. Collectively, our findings demonstrate the effectiveness of flubendazole in combination with paclitaxel for treating BC, providing an insight into exploiting more novel combination therapies for BC in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.
- Sichuan Engineering Research Center for Biomimetic Synthesis of Natural Drugs, School of Life Science and Engineering, Southwest Jiaotong University, Chengdu 610031, China.
Förderung
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
- Post-Doctor Research Project
- Post-Doctor Research Project of West China Hospital, Sichuan Universit
- Disciplines of excellence, West China Hospital, Sichuan University
Zitieren
APA
Zhou, Y., Liao, M., Li, Z., Ye, J., Wu, L., Mou, Y., Fu, L., & Zhen, Y. (2023). Flubendazole Enhances the Inhibitory Effect of Paclitaxel via HIF1α/PI3K/AKT Signaling Pathways in Breast Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242015121
Vancouver
Zhou Y, Liao M, Li Z, Ye J, Wu L, Mou Y, et al. Flubendazole Enhances the Inhibitory Effect of Paclitaxel via HIF1α/PI3K/AKT Signaling Pathways in Breast Cancer. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242015121
BibTeX
@article{Zhou2023,
author = {Zhou, Yuxin and Liao, Minru and Li, Zixiang and Ye, Jing and Wu, Lifeng and Mou, Yi and Fu, Leilei and Zhen, Yongqi},
title = {Flubendazole Enhances the Inhibitory Effect of Paclitaxel via HIF1α/PI3K/AKT Signaling Pathways in Breast Cancer},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms242015121}
}
EUVIMED